Goldman Sachs
CRBU icon

Goldman Sachs’s Caribou Biosciences CRBU Stock Holding History

Goldman Sachs’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$716K Sell
376,589
-112,549
-23% -$193K ﹤0.01% 5334
2025
Q4 		$778K Buy
489,138
+244,314
+100% +$513K ﹤0.01% 5303
2025
Q3 		$570K Sell
244,824
-546,792
-69% -$1.03M ﹤0.01% 5428
2025
Q2 		$997K Sell
791,616
-31,224
-4% -$30.7K ﹤0.01% 4709
2025
Q1 		$751K Sell
822,840
-247,696
-23% -$322K ﹤0.01% 4915
2024
Q4 		$1.7M Buy
1,070,536
+369,644
+53% +$743K ﹤0.01% 4426
2024
Q3 		$1.37M Sell
700,892
-487,872
-41% -$999K ﹤0.01% 4424
2024
Q2 		$1.95M Buy
1,188,764
+585,862
+97% +$1.87M ﹤0.01% 3946
2024
Q1 		$3.1M Sell
602,902
-57,138
-9% -$352K ﹤0.01% 3515
2023
Q4 		$3.78M Buy
660,040
+264,431
+67% +$1.31M ﹤0.01% 3393
2023
Q3 		$1.89M Buy
395,609
+124,968
+46% +$775K ﹤0.01% 3814
2023
Q2 		$1.15M Sell
270,641
-43,128
-14% -$194K ﹤0.01% 4253
2023
Q1 		$1.67M Sell
313,769
-39,128
-11% -$244K ﹤0.01% 4004
2022
Q4 		$2.22M Sell
352,897
-215,432
-38% -$1.92M ﹤0.01% 3866
2022
Q3 		$6M Buy
568,329
+428,011
+305% +$3.99M ﹤0.01% 2981
2022
Q2 		$761K Sell
140,318
-139,140
-50% -$1.06M ﹤0.01% 4807
2022
Q1 		$2.57M Buy
279,458
+247,735
+781% +$2.61M ﹤0.01% 4009
2021
Q4 		$478K Buy
+31,723
New +$617K ﹤0.01% 5418

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's CRBU Position: Q1 2026 in Review

Goldman Sachs reduced its Caribou Biosciences (CRBU) stake by 23% in Q1 2026, selling an estimated $193K and leaving 376,589 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #5334.

Goldman Sachs first reported a position in CRBU in Q4 2021 and has held it in 18 quarters since. The position peaked at $6M in Q3 2022. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Goldman Sachs held 376,589 shares of Caribou Biosciences worth $716K as of Q1 2026.
  • Goldman Sachs sold 112,549 Caribou Biosciences shares in Q1 2026, an estimated $193K.
  • Caribou Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5334 holding.
  • Goldman Sachs first reported a position in Caribou Biosciences in Q4 2021 and has held it in 18 quarters since.
  • Goldman Sachs's Caribou Biosciences position peaked at $6M in Q3 2022.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.